乗り物酔いによる吐き気と嘔吐市場 - 市場の洞察、疫学、市場予測：2032年

工業化と交通手段の拡大により、米国では乗り物酔いによる吐き気や嘔吐が増加しています。吐き気や嘔吐は旅行中によく認識される現象であるため、個人がこの症状を認識し識別することは容易です。乗り物酔いによる吐き気や嘔吐を治療する有効な治療法はありません。管理には、非薬理学的および薬理学的な予防・治療法を含む集学的アプローチが必要です。抗コリン薬（スコポラミン経皮パッチ）、抗ヒスタミン薬（シクリジン、ジメンヒドリナート、プロメタジン、メクリジンなど）、制吐薬など、いくつかの一般用医薬品やジェネリック医薬品は、症状の予防や軽減に役立ちます。

乗り物酔いにおける吐き気や嘔吐の根底にある正確なメカニズムは複雑で、よくわかっていません。しかし、目が感知するものと内耳の前庭系が感知するものとの間の断絶によって引き起こされ、吐き気や嘔吐のような症状につながると考えられています。

主要7ヶ国における乗り物酔いによる吐き気と嘔吐の総市場規模は、2022年に約7億9,606万米ドルであり、予測期間中（2023年～2032年）に拡大すると予測されています。主要7ヶ国の中で乗り物酔いによる吐き気と嘔吐の市場シェアは米国が最も大きく、2022年には約5億2,632万米ドルの収益となり、人口増加や新たな治療法の発売により予測期間中に増加するとみられます。EU4ヶ国と英国の中で、フランスは2022年に乗り物酔いによる吐き気と嘔吐の最大市場規模を占め、スペインは最下位を占めました。日本は、乗り物酔いによる吐き気と嘔吐の市場シェアで主要7ヶ国中第2位を占め、2022年の収益は約9,506万米ドルであったが、予測期間中も変動が予想されます。

当レポートでは、主要7ヶ国における乗り物酔いによる吐き気と嘔吐市場について調査し、市場の概要とともに、疫学、患者動向、新たな治療法、2032年までの市場規模予測、および医療のアンメットニーズなどを提供しています。

目次

第1章 重要な洞察

第2章 レポートのイントロダクション

第3章 乗り物酔いによる吐き気と嘔吐の市場概要

第4章 乗り物酔いによる吐き気と嘔吐の調査手法と疫学と市場

第5章 乗り物酔いによる吐き気と嘔吐のエグゼクティブサマリー

第6章 主要な出来事

第7章 疾患の背景と概要

• 乗り物酔いにおける吐き気と嘔吐イントロダクション
• 兆候と症状
• 病因
• 危険因子
• 合併症
• 病態生理学
• 診断
• 治療

第8章 患者動向

第9章 疫学と患者数

• 主な調査結果
• 仮定と根拠：主要7ヶ国
• 主要7ヶ国における乗り物酔いの総症例数
• 主要7ヶ国における乗り物酔いによる吐き気と嘔吐の総症例数
• 米国
• EU4ヶ国と英国
• 日本

第10章 新興薬剤

第11章 乗り物酔いによる吐き気と嘔吐：市場分析

• 主な調査結果
• 主要な市場予測の前提条件
• 市場の見通し
• コンジョイント分析
• 主要7ヶ国における乗り物酔いによる吐き気と嘔吐の総市場規模
• 主要7ヶ国における乗り物酔いによる吐き気と嘔吐の別市場規模、治療法別
• 米国における乗り物酔いによる吐き気と嘔吐の市場規模
• EU4ヶ国および英国における乗り物酔いによる吐き気と嘔吐の市場規模
• 日本における乗り物酔いによる吐き気と嘔吐の市場規模

第12章 主要なオピニオンリーダーの見解

第13章 SWOT分析

第14章 アンメットニーズ

第15章 市場アクセスと償還

第16章 付録

第17章 DelveInsightのサービス内容

第18章 免責事項

第19章 DelveInsightについて

List of Tables

• Table 1: Summary of Market and Epidemiology (2019-2032)
• Table 2: Key Events for Nausea and Vomiting Induced by Motion Sickness
• Table 3: Signs and Symptoms of Motion Sickness
• Table 4: Total Cases of Motion Sickness in the 7MM, in thousands (2019-2032)
• Table 5: Total Cases of Nausea and Vomiting Induced by Motion Sickness in the 7MM, in thousands (2019-2032)
• Table 6: Total Cases of Motion Sickness in the US, in thousands (2019-2032)
• Table 7: Total Cases of Motion Sickness by Mode of Transport in the US, in thousands (2019-2032)
• Table 8: Total Cases of Nausea and Vomiting in Motion Sickness by Mode of Transport in the US, in thousands (2019-2032)
• Table 9: Total Cases of Motion Sickness in EU4 and the UK, in thousands (2019-2032)
• Table 10: Total Cases of Motion Sickness by Mode of Transport in EU4 and the UK, in thousands (2019-2032)
• Table 11: Total Cases of Nausea and Vomiting in Motion Sickness by Mode of Transport in EU4 and the UK, in thousands (2019-2032)
• Table 12: Total Cases of Motion Sickness in Japan, in thousands (2019-2032)
• Table 13: Total Cases of Motion Sickness by Mode of Transport in Japan, in thousands (2019-2032)
• Table 14: Total Cases of Nausea and Vomiting in Motion Sickness by Mode of Transport in Japan, in thousands (2019-2032)
• Table 15: Comparison of Emerging Drugs
• Table 16: DPI-386 (scopolamine gel), Clinical Trial Description, 2023
• Table 17: VLY-686 (tradipitant), Clinical Trial Description, 2023
• Table 18: Key Market Forecast Assumptions for DPI-386
• Table 19: Key Market Forecast Assumptions for VLY-686 (tradipitant)
• Table 20: Total Market Size of Nausea and Vomiting Induced by Motion Sickness in the 7MM, in USD million (2019-2032)
• Table 21: Total Market Size by Therapies for Nausea and Vomiting Induced by Motion Sickness in the 7MM, in USD million (2019-2032)
• Table 22: Total Market Size of Nausea and Vomiting Induced by Motion Sickness in the US, in USD million (2019-2032)
• Table 23: The Market Size of Nausea and Vomiting Induced by Motion Sickness by Therapies in the US, in USD million (2019-2032)
• Table 24: Total Market Size of Nausea and Vomiting Induced by Motion Sickness in EU4 and the UK, in USD million (2019-2032)
• Table 25: The Market Size of Nausea and Vomiting Induced by Motion Sickness by Therapies in EU4 and the UK, in USD million (2019-2032)
• Table 26: Total Market Size of Nausea and Vomiting Induced by Motion Sickness in Japan, in USD million (2019-2032)
• Table 27: The Market Size of Nausea and Vomiting Induced by Motion Sickness by Therapies in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: Risk Factors
• Figure 2: Sensory Conflict Theory for Motion Sickness
• Figure 3: An Overview of Underlying Mechanisms Involved in Nausea
• Figure 4: Treatment Approach for Nausea and Vomiting in Motion Sickness
• Figure 5: Patient Journey of Nausea and Vomiting Induced by Motion Sickness
• Figure 6: Total Cases of Motion Sickness in the 7MM (2019-2032)
• Figure 7: Total Cases of Nausea and Vomiting Induced by Motion Sickness in the 7MM (2019-2032)
• Figure 8: Total Cases of Motion Sickness in the US (2019-2032)
• Figure 9: Total Cases of Motion Sickness by Mode of Transport in the US (2019-2032)
• Figure 10: Total Cases of Nausea and Vomiting in Motion Sickness by Mode of Transport in the US (2019-2032)
• Figure 11: Total Cases of Motion Sickness in EU4 and the UK (2019-2032)
• Figure 12: Total Cases of Motion Sickness by Mode of Transport in EU4 and the UK (2019-2032)
• Figure 13: Total Cases of Nausea and Vomiting in Motion Sickness by Mode of Transport in EU4 and the UK (2019-2032)
• Figure 14: Total Cases of Motion Sickness in Japan (2019-2032)
• Figure 15: Total Cases of Motion Sickness by Mode of Transport in Japan (2019-2032)
• Figure 16: Total Cases of Nausea and Vomiting in Motion Sickness by Mode of Transport in Japan (2019-2032)
• Figure 17: Total Market Size of Nausea and Vomiting Induced by Motion Sickness in the 7MM, in USD million (2019-2032)
• Figure 18: Total Market Size by Therapies for Nausea and Vomiting Induced by Motion Sickness in the 7MM, in USD million (2019-2032)
• Figure 19: Total Market Size of Nausea and Vomiting Induced by Motion Sickness in the US, in USD million (2019-2032)
• Figure 20: The Market Size by Therapies for Nausea and Vomiting Induced by Motion Sickness in the US, in USD million (2019-2032)
• Figure 21: Total Market Size of Nausea and Vomiting Induced by Motion Sickness in EU4 and the UK, in USD million (2019-2032)
• Figure 22: The Market Size of Nausea and Vomiting Induced by Motion Sickness by Therapies in EU4 and the UK, in USD million (2019-2032)
• Figure 23: Total Market Size of Nausea and Vomiting Induced by Motion Sickness in Japan, in USD million (2019-2032)
• Figure 24: The Market Size of Nausea and Vomiting Induced by Motion Sickness by Therapies in Japan, in USD million (2019-2032)
• Figure 25: SWOT Analysis of Nausea and Vomiting Induced by Motion Sickness
• Figure 26: Unmet Needs of Nausea and Vomiting Induced by Motion
• Figure 27: Health Technology Assessment
• Figure 28: Reimbursement Process in Germany
• Figure 29: Reimbursement Process in France
• Figure 30: Reimbursement Process in Italy
• Figure 31: Reimbursement Process in Spain
• Figure 32: Reimbursement Process in the United Kingdom
• Figure 33: Reimbursement Process in Japan

Key Highlights:

• Industrialization and expansion of modes of transport have led to an increase in nausea and vomiting induced by motion sickness in the US.
• Nausea and vomiting are well-recognized phenomena during travel, making it easier for individuals to recognize and identify the condition.
• There is no effective therapy to treat nausea and vomiting induced by motion sickness. The management involves a multidisciplinary approach, including nonpharmacological and pharmacological prevention and treatment options. Several OTC and generic drugs, including anticholinergics (scopolamine transdermal patches), antihistamines (cyclizine, dimenhydrinate, promethazine, meclizine, and others), and anti-emetics help prevent or reduce symptoms.
• Nonpharmacological therapies like behavioral and environmental modification and herbs may provide some relief. Herbs like ginger, lemon, fennel, peppermint, etc., and enhancing visual focus by aligning visual and vestibular cues in the direction of motion and other behavioral methods often prevent nausea and vomiting while traveling.
• The exact mechanism of underlying nausea and vomiting in motion sickness is complex and poorly understood. However, it is believed to be caused by a disconnect between what the eyes perceive and the inner ear's vestibular system senses, leading to symptoms like nausea and vomiting.
• There is an opportunity for companies to invest in refining animal models that better mimic human experiences of nausea and vomiting to understand its pathophysiology and support clinical trials.
• The major concern in understanding the market for nausea and vomiting induced by motion sickness is a lack of epidemiology data and a paucity of evidence to validate interventions used in management. Further, the lack of established diagnostic and treatment guidelines for nausea and vomiting induced by motion sickness results in variability and therapy uncertainty.
• In 2022, the market size of nausea and vomiting induced by motion sickness was highest in the US among the 7MM, accounting for approximately USD 526.32 million. It is expected to increase by 2032.
• In EU4 and the UK, the current standard of care involves treatment with therapies like scopolamine, ondansetron, and others, generating a revenue of USD 174.69 million in 2022.
• The available treatment is limited by partial efficacy and unwanted side effects. Scopolamine is a nonselective anticholinergic agent and is the most effective and widely prescribed agent; however, it is associated with side effects like dry eyes/mouth, drowsiness, and tachycardia.
• Advances in research have led to the discovery of gel formulation and intranasal route of scopolamine that provides rapid onset of action.
• Emerging therapies, DPI-386 (scopolamine gel) and VLY-686 (tradipitant), can potentially create a positive shift in the market size of nausea and vomiting induced by motion sickness during the forecast period.

DelveInsight's "Nausea and Vomiting Induced by Motion Sickness - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the nausea and vomiting induced by motion sickness historical and forecasted epidemiology as well as the market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The nausea and vomiting induced by motion sickness market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted the 7MM nausea and vomiting induced by motion sickness market size from 2019 to 2032. The report also covers current nausea and vomiting induced by motion sickness treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032

Nausea and Vomiting Induced by Motion Sickness Understanding and Treatment Algorithm

Nausea and Vomiting Induced by Motion Sickness Overview

Motion sickness is a common physiological response that occurs when there is a sensory mismatch between the visual and vestibular systems. It usually manifests during the air, car, bus, train, or boat travel, leading to hallmark symptoms, nausea and vomiting.

The severity of symptoms can vary from mild discomfort to more severe reactions. Mild symptoms include malaise, headache, irritability, drowsiness, fatigue, etc. Moderate symptoms include nonvertiginous dizziness, apathy, depression, and disinterest in social activities, and severe symptoms include incapacitation, loss of postural stability, persistent retching, and social isolation of the individual.

Nausea is a subjective sensation that signals imminent emesis, while vomiting is the forceful removal of gastrointestinal contents. The sensation of nausea and the ability to vomit are key components of human defenses against motion sickness caused by traveling (car rides, bus rides, air travel, and boat trips) or unintentional ingestion of noxious material.

The exact mechanism of underlying nausea and vomiting in motion sickness is complex and poorly understood. However, it is believed to involve complex interactions between the inner ear, brainstem, and autonomic nervous system. The brain's attempts to resolve sensory conflicts can activate vomiting centers, triggering the reflexive response.

Factors such as susceptibility due to genetics, previous experiences, and individual sensitivities increase the likelihood of developing motion sickness in individuals.

Nausea and Vomiting Induced by Motion Sickness Diagnosis

The clinical diagnosis of motion sickness includes a physical examination to rule out other possible causes of similar symptoms. The diagnostic methodology may include an evaluation of medical history, symptom description, activity history, motion challenge test, and physical examination. Additional workup through laboratory or radiographic tests is not required if a patient has a typical presentation or a prior history of motion sickness. Differential diagnoses of motion sickness include migraine, pregnancy, concussion, intoxication, hangover, basilar artery occlusion, cerebral vascular accident, vestibulopathy, hypoglycemia, depression, and anxiety.

Further details related to country-based variations are provided in the report…

Nausea and Vomiting Induced by Motion Sickness Treatment

A multidisciplinary approach involving both pharmacological and nonpharmacological agents treats or helps prevent nausea and vomiting induced by motion sickness. A visual focus, a distant point, appropriate ventilation, fresh air, preserving body posture, and controlling attentive breathing are behavioral strategies that can assist in minimizing the sensory conflict between the eyes and the inner ear. Over time, some individuals can become less sensitive to motion sickness through repeated exposure to the triggering motion. For example, sailors may experience reduced symptoms after spending more time at sea.

Motion sickness medications are only sporadically useful and can have negative side effects. The drugs should be tested securely before being used at work or traveling. There are three subcategories of medications: Sympathomimetic, anticholinergic, and antihistamine.

Scopolamine patch and promethazine are anticholinergic drugs that prevent motion sickness by obstructing signals from the vestibular system to the brain's vomiting center. Scopolamine transdermal patches deliver long-lasting comfort behind the ear. Antihistamines such as promethazine, dimenhydrinate, cyclizine, meclizine, and cinnarizine are also used. They work by obstructing histamine receptors in the brain, lowering vestibular sensitivity, and decreasing the brain's reaction to motion-related signals, all of which help prevent motion sickness. Further, H1-antihistamines with the lowest possible potential for sedation are the main treatment for vertigo, nausea, and vomiting due to motion sickness.

Nausea and Vomiting Induced by Motion Sickness Epidemiology

As the market is derived using a patient-based model, the nausea and vomiting induced by motion sickness epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total cases of motion sickness, total cases of motion sickness by mode of transport, total cases of nausea and vomiting in motion sickness by mode of transport in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2019 to 2032.

• In 2022, there were approximately 217,237,382 total cases of motion sickness in the 7MM. These cases are expected to increase by 2032.
• In 2022, among the 7MM, the US accounted for the highest cases of motion sickness, contributing nearly 52%, while Japan accounted for the least, with around 14% of the total cases of motion sickness.
• Among EU4 and the UK, France accounted for the highest cases of motion sickness with around 17,076,287 cases, followed by the UK with 16,947,850 cases, while Spain accounted for the least cases, 11,790,855, in 2022.
• In the US, motion sickness due to travel by car and bus was the highest, with 33,734,195 cases in each mode. This was followed by motion sickness due to travel by train with 22,489,464 cases, airplanes with 16,867,098 cases, and others in 2022. These cases are projected to increase by 2032.
• In EU4 and the UK, based on the modes of transport, around 30% of motion sickness cases occur when traveling by car and bus in each of the two modes, followed by nearly 20% of cases by train, 15% by airplane, and 5% by boat/ship, in 2022.
• In 2022, in Germany, around 3,794,248 individuals had nausea, and 682,965 had vomiting traveled by car and bus, while 346,624 and 190,894 individuals had nausea and vomiting, respectively, while traveling by boat/ship.

In 2022, Japan accounted for the second-highest cases of motion sickness among the 7MM, with nearly 31,053,692 cases, of which 15,247,363 individuals had nausea and vomiting. These cases are expected to change during the forecast period.

Nausea and Vomiting Induced by Motion Sickness Drug Chapters

The drug chapter segment of nausea and vomiting induced by motion sickness report encloses a detailed analysis of nausea and vomiting induced by motion sickness, currently used drugs, and late-stage (Phase III) pipeline drugs. It also helps understand the nausea and vomiting induced by motion sickness clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs

DPI-386 (scopolamine gel): Defender Pharmaceuticals

DPI-386 is a low-dose intranasal scopolamine gel investigated by Defender Pharmaceutical, also called Repurposed Therapeutics. Scopolamine is a naturally occurring muscarinic receptor antagonist and belladonna alkaloid. It competitively inhibits G-protein coupled post-ganglionic muscarinic receptors for acetylcholine and acts as a nonselective muscarinic antagonist, producing both peripheral antimuscarinic properties and central sedative, anti-emetic, and amnestic effects. TRANSDERM SCOP (scopolamine transdermal patch [TDS]) is approved for postoperative nausea and vomiting (PONV) associated with recovery from anesthesia, opiate analgesia, and surgery and nausea and vomiting associated with motion sickness.

DPI-386 is undergoing Phase II trials to mitigate G-transition-induced motion sickness and has filed for US FDA approval to prevent nausea and vomiting induced by motion, with anticipated acceptance by September 2023. Further, the company is also investigating the drug for treating PONV and virtual reality.

Note: Detailed emerging therapies assessment will be provided in the final report.

Drug Class Insights

Current treatment approaches for nausea and vomiting induced by motion sickness are limited, with marginal efficacy and undesirable side effects. Different classes of therapies like anticholinesterase (scopolamine), antihistamines, anti-emetics, and others prevent or treat symptoms. Scopolamine is a nonselective anticholinergic agent and is presently the most effective and prescribed agent. Besides, many first-generation antihistamines effectively prevent and treat motion sickness, including cinnarizine, promethazine, dimenhydrinate, diphenhydramine, and others. Further, anti-emetics like ondansetron, a 5-HT3 receptor antagonist, are sometimes used to inhibit gastric tachyarrhythmia to treat vomiting.

Antihistamines: First-generation antihistamines are used to treat motion sickness. A histaminergic neuron system is involved in the symptomatic mechanism of motion sickness via H1-receptors; this group of medicines can reduce the severity of the symptoms and signs of motion sickness by blocking the emetic linkage. They are generally recommended for patients who can tolerate their sedative effects. Cyclizine (Marezine), dimenhydrinate, promethazine, and meclizine (Antivert) demonstrate effectiveness.

Note: Detailed assessment will be provided in the final report.

Nausea and Vomiting Induced by Motion Sickness Market Outlook

Nausea and vomiting are common occurrences after a triggering motion or event, usually known as motion sickness. Motion sickness is a condition that occurs when there is a disconnect between the sensory inputs the brain receives. This disconnect can happen when conflicting signals are sent by the inner ears, eyes, and other sensory receptors to the brain regarding the body's motion and orientation. It can occur in various situations when traveling by car, boat, airplane, amusement park rides, etc. The conflicting sensory inputs can lead to symptoms like nausea, vomiting, dizziness, sweating, and general discomfort. It is usually diagnosed through history and physical examination. Treatment involves a combination of preventive measures, lifestyle changes, and, in some cases, medications.

Largely, the market of nausea and vomiting induced by motion sickness is occupied by over-the-counter (OTC) medications and generic forms of antihistamines, anticholinergics, benzodiazepines, dopamine receptor antagonists, and sympathomimetics, and others are also used. Over the past four decades, since the approval of the scopolamine transdermal patch, no other treatment has been approved by the US FDA for treating nausea and vomiting induced by motion sickness, and no consensus treatment guidelines are available.

Besides, nonpharmacological treatments relieve nausea and vomiting in motion sickness, for instance, reducing sensory conflict. Supplements and herbs are commonly used for nausea and may relieve motion sickness; however, no credible studies show that herbs used for motion sickness treatment are safe or work. Ginger, peppermint, black horehound, and others are being used. Further, acupressure bands are commercially available that may help reduce symptoms of motion sickness or delay its onset. Homeopathic remedies like Borax, Cocclus, Nux Vomica, Petroleum, Sepia, and others are sometimes used for nausea.

Further, awareness and avoidance of situations that trigger symptoms are the primary defenses against motion sickness. Looking outside the window, rapid and shallow breathing, sitting in the front of a car or bus, avoiding smoking, and eating small amounts of food frequently are common preventive measures for nausea and vomiting during travel.

The current market has been covered by various drugs used off-label across the 7MM. Different therapies like anticholinesterase (scopolamine), antihistamines, anti-emetics, and others were the major drug classes considered for the current treatment in the forecast model.

Key players Defender Pharmaceuticals (DPI-386 [scopolamine gel]), Vanda Pharmaceuticals, and Eli Lilly's VLY-686 (tradipitant) are evaluating their lead candidates in the late stages of clinical development. They aim to investigate their products for treating nausea and vomiting induced by motion sickness.

• The total market size of nausea and vomiting induced by motion sickness in the 7MM was approximately USD 796.06 million in 2022 and is projected to increase during the forecast period (2023-2032).
• According to DelveInsight's estimates, among the 7MM, the US had the largest market share for nausea and vomiting induced by motion sickness, with a revenue of nearly USD 526.32 million in 2022, and will increase during the forecast period due to increasing population and the launch of the emerging therapies.
• Among EU4 and the UK countries, France accounted for the maximum market size of nausea and vomiting induced by motion sickness in 2022, while Spain occupied the bottom of the ladder.
• Japan captured the second largest market share of nausea and vomiting induced by motion sickness among the 7MM, with a revenue of approximately USD 95.06 million in 2022, expected to change during the forecast period.
• In Japan, the standard of care accounted for around USD 95.06 million in 2022, which is expected to decrease with the entry of new therapies in the market by 2032.
• Though the pipeline is limited, two therapies, DPI-386 (scopolamine gel) and VLY-686 (tradipitant), will enter the market during the forecast period.
• Vanda Pharmaceuticals and Eli Lilly's VLY-686 (tradipitant) is a small NK-1 receptor antagonist that prevents vomiting. It is anticipated to enter the US market by 2025, generating a revenue of USD 0.77 million in its entry year.
• Defender Pharmaceuticals' DPI-386 (scopolamine gel) will attain its peak share by the seventh year and will capture nearly 35% of total nausea and vomiting induced by the motion sickness market in EU4 and the UK by 2032.

Nausea and Vomiting Induced by Motion Sickness Drugs Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during 2019-2032. For example, DPI-386 (scopolamine gel) is a low-dose intranasal scopolamine gel expected to enter the US market by 2024 with a slow-medium uptake due to competition from the available therapies.

Further detailed analysis of emerging therapies drug uptake in the report…

Nausea and Vomiting Induced by Motion Sickness Pipeline Development Activities

The report provides insights into therapeutic candidates in Phase III. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for emerging therapies for nausea and vomiting induced by motion sickness.

KOL Views

To keep up with current market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts were contacted for insights on nausea and vomiting induced by motion sickness evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, and drug uptake, along with challenges related to accessibility, including Medical/scientific writers, Medical Professionals, Professors, Directors, and Others.

DelveInsight's analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. Centers like the University of Vermont, Southwestern Oklahoma State University, University of California, Barcelona San Joan de Deu Center, University of Manchester, and Juntendo University Shizuoka Hospital were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns for nausea and vomiting induced by motion sickness market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Physician's View

According to our primary research analysis, though there is a lack of treatment guidelines and approved therapies, the commonly prescribed pharmacological treatments are anticholinergics, antihistamines, and anti-emetics, while other treatments like dopamine receptor antagonists, sympathomimetics, and benzodiazepines are rarely used. Further, the scopolamine transdermal patch, the most effective and widely prescribed agent, acts as a nonselective antimuscarinic by inhibiting input to the vestibular nuclei.

Apart from medicinal therapies, the market is affected by other preventive nonpharmacological measures, including sensory input modification, homeopathic remedies, and ginger. Although ginger is most commonly used as a culinary spice, it is believed to have many medicinal properties, including treating motion sickness. Further, some behavioral measures prevent motion sickness by modifying the sensory pattern responsible for the neural mismatch signal.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. The effectiveness of these therapies was analyzed by giving them scores based on a reduction in the incidence of vomiting and motion sickness.

The therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed. It sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Market Access and Reimbursement

Reimbursement is the price negotiation between the manufacturer and payer that allows the manufacturer access to that market. It is provided to reduce the high costs and make essential drugs affordable. Market access refers to all patients' ability to access a given product quickly, conveniently, and affordably.

Several drugs are available as OTC or off-label for treating nausea and vomiting induced by motion sickness. However, there is a lack of approved and effective therapies; TRANDERM SCOP is the only approved drug for nausea and vomiting associated with motion sickness. Hence, there is limited accessibility to treatment, and management relies on a multidisciplinary approach, including OTC drug, nonpharmacological, and pharmacological approaches.

Capital District Physicians' Health Plan (CDPHP) Medicare Advantage Drug Plans generally cover scopolamine as long as the drug is medically necessary, the prescription is filled at a CDPHP Medicare Advantage Drug Plans network pharmacy, and other plan rules are followed. Scopolamine 1 mg/3 days patch 72 h falls under drug Tier 3 preferred brand in which Network Retail Cost Sharing (30-day supply) provides USD 40-47 copayment, depending upon the plan.

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of nausea and vomiting induced by motion sickness, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression, and treatment guidelines have been provided.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current treatment landscape.
• A detailed review of the nausea and vomiting induced by the motion sickness market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis, expert insights/KOL views, patient journey, and treatment preferences that help shape and drive the 7MM nausea and vomiting induced by the motion sickness market.

Nausea and Vomiting Induced by Motion Sickness Report Insights

• Patient Population
• Therapeutic Approaches
• Nausea and Vomiting Induced by Motion Sickness Pipeline Analysis
• Nausea and Vomiting Induced by Motion Sickness Market Size and Trends
• Existing and Future Market Opportunity

Nausea and Vomiting Induced by Motion Sickness Report Key Strengths

• 10 years Forecast
• The 7MM Coverage
• Nausea and Vomiting Induced by Motion Sickness Epidemiology Segmentation
• Key Cross Competition
• Conjoint Analysis
• Drugs Uptake and Key Market Forecast Assumptions

Nausea and Vomiting Induced by Motion Sickness Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)

Key Questions

Market Insights

• What was the total market size of nausea and vomiting induced by motion sickness, the market size by therapies for nausea and vomiting induced by motion sickness, market share (%) distribution in 2019, and what would it look like by 2032? What are the contributing factors for this growth?
• How will DPI-386 (scopolamine gel) and VLY-686 (tradipitant) affect nausea and vomiting induced by the motion sickness treatment paradigm?
• How will current therapies compete with other emerging therapies?
• Which drug is going to be the largest contributor by 2032?
• What are the pricing variations among different geographies for off-label therapies?
• How would future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights

• What are the disease risks, burdens, and unmet needs of nausea and vomiting induced by motion sickness? What will be the growth opportunities across the 7MM with respect to the patient population pertaining to nausea and vomiting induced by motion sickness?
• What is the historical and forecasted patient pool of nausea and vomiting induced by motion sickness in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Out of the countries mentioned above, which country would have the highest cases of nausea and vomiting induced by motion sickness during the forecast period (2023-2032)?
• What factors contribute to the growth of nausea and vomiting induced by motion sickness cases?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies

• What are the current options to treat nausea and vomiting induced by motion sickness?
• How many companies are developing therapies for treating nausea and vomiting induced by motion sickness?
• How many emerging therapies are in the late stage of development for treating nausea and vomiting induced by motion sickness?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitations of existing therapies?
• What is the cost burden of current treatment on the patient?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the accessibility issues of approved therapy in the US?
• What is the 7MM historical and forecasted market of nausea and vomiting induced by motion sickness?

Reasons to Buy:

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the nausea and vomiting induced by the motion sickness market.
• Insights on patient burden, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• The distribution of historical and current patient share is based on real-world prescription data in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Nausea and Vomiting Induced by Motion Sickness Market Overview at a Glance

• 3.1. Market Share (%) Distribution of Nausea and Vomiting Induced by Motion Sickness in 2019
• 3.2. Market Share (%) Distribution of Nausea and Vomiting Induced by Motion Sickness in 2032

4. Methodology of Nausea and Vomiting Induced by Motion Sickness Epidemiology and Market

5. Executive Summary of Nausea and Vomiting Induced by Motion Sickness

6. Key Events

7. Disease Background and Overview

• 7.1. Introduction to Nausea and Vomiting in Motion Sickness
• 7.2. Signs and Symptoms
• 7.3. Etiology
• 7.4. Risk Factors
• 7.5. Complication
• 7.6. Pathophysiology
  • 7.6.1. Sensory Conflict Theory
  • 7.6.2. Genetic Contribution
• 7.7. Diagnosis
  • 7.7.1. Differential Diagnosis
  • 7.7.2. Motion Sickness Diagnostic Criteria: Committee of the Barany Society
• 7.8. Treatment
  • 7.8.1. Pharmacological Treatment
  • 7.8.2. Nonpharmacological Countermeasures
  • 7.8.3. Behavioral Strategies to Prevent Nausea and Vomiting in Motion Sickness

8. Patient Journey

9. Epidemiology and Patient Population

• 9.1. Key Findings
• 9.2. Assumptions and Rationale: The 7MM
  • 9.2.1. Cases of Motion Sickness
  • 9.2.2. Cases of Motion Sickness by Mode of Transport
  • 9.2.3. Cases of Nausea and Vomiting in Motion Sickness by Mode of Transport
• 9.3. Total Cases of Motion Sickness in the 7MM
• 9.4. Total Cases of Nausea and Vomiting Induced by Motion Sickness in the 7MM
• 9.5. The US
  • 9.5.1. Total Cases of Motion Sickness in the US
  • 9.5.2. Total Cases of Motion Sickness by Mode of Transport in the US
  • 9.5.3. Total Cases of Nausea and Vomiting in Motion Sickness by Mode of Transport in the US
• 9.6. EU4 and the UK
  • 9.6.1. Total Cases of Motion Sickness in EU4 and the UK
  • 9.6.2. Total Cases of Motion Sickness by Mode of Transport in EU4 and the UK
  • 9.6.3. Total Cases of Nausea and Vomiting in Motion Sickness by Mode of Transport in EU4 and the UK
• 9.7. Japan
  • 9.7.1. Total Cases of Motion Sickness in Japan
  • 9.7.2. Total Cases of Motion Sickness by Mode of Transport in Japan
  • 9.7.3. Total Cases of Nausea and Vomiting in Motion Sickness by Mode of Transport in Japan

10. Emerging Drugs

• 10.1. Key Cross Competition
• 10.2. DPI-386 (scopolamine gel): Defender Pharmaceuticals
  • 10.2.1. Drug Description
  • 10.2.2. Other Developmental Activity
  • 10.2.3. Clinical Development
  • 10.2.4. Clinical Trials Information
  • 10.2.5. Safety and Efficacy
  • 10.2.6. Product Profile
  • 10.2.7. Analysts' Views
• 10.3. VLY-686 (tradipitant): Vanda Pharmaceuticals/Eli Lilly
  • 10.3.1. Drug Description
  • 10.3.2. Other Developmental Activity
  • 10.3.3. Clinical Development
  • 10.3.4. Clinical Trials Information
  • 10.3.5. Safety and Efficacy
  • 10.3.6. Product Profile
  • 10.3.7. Analysts' Views

11. Nausea and Vomiting Induced by Motion Sickness: Market Analysis

• 11.1. Key Findings
• 11.2. Key Market Forecast Assumptions
• 11.3. Market Outlook
• 11.4. Conjoint Analysis
• 11.5. Total Market Size of Nausea and Vomiting Induced by Motion Sickness in the 7MM
• 11.6. Total Market Size by Therapies for Nausea and Vomiting Induced by Motion Sickness in the 7MM
• 11.7. Market Size of Nausea and Vomiting Induced by Motion Sickness in the US
  • 11.7.1. Total Market Size of Nausea and Vomiting Induced by Motion Sickness in the US
  • 11.7.2. The Market Size by Therapies for Nausea and Vomiting Induced by Motion Sickness in the US
• 11.8. Market Size of Nausea and Vomiting Induced by Motion Sickness in EU4 and the UK
  • 11.8.1. Total Market Size of Nausea and Vomiting Induced by Motion Sickness in EU4 and the UK
  • 11.8.2. The Market Size by Therapies for Nausea and Vomiting Induced by Motion Sickness in EU4 and the UK
• 11.9. Market Size of Nausea and Vomiting Induced by Motion Sickness in Japan
  • 11.9.1. Total Market Size of Nausea and Vomiting Induced by Motion Sickness in Japan
  • 11.9.2. The Market Size by Therapies for Nausea and Vomiting Induced by Motion Sickness in Japan

12. Key Opinion Leaders' Views

13. SWOT Analysis

14. Unmet Needs

15. Market Access and Reimbursement

• 15.1. The United States
  • 15.1.1. Center for Medicare & Medicaid Services (CMS)
• 15.2. In EU4 and the UK
  • 15.2.1. Germany
  • 15.2.2. France
  • 15.2.3. Italy
  • 15.2.4. Spain
  • 15.2.5. The United Kingdom
• 15.3. Japan
  • 15.3.1. MHLW

16. Appendix

• 16.1. Bibliography
• 16.2. Acronyms and Abbreviations
• 16.3. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight